Gentamicin

Concomitant administration is contraindicated due to nephrotoxic potential. Must be discontinued at least 7 days prior to cidofovir therapy.

Concomitant administration of cidofovir and gentamicin is contraindicated due to nephrotoxic potential. Must be discontinued at least 7 days prior to cidofovir therapy.

Increases digoxin serum concentration by 129-212%. Requires monitoring and dose reduction of 30-50%.

Indomethacin significantly elevates both peak and trough levels of gentamicin in premature infants, potentially increasing aminoglycoside toxicity risk.

Parenteral administration may intensify or produce neuromuscular block and paralysis when used with pyridostigmine.

Gentamicin may intensify or produce neuromuscular block on its own and can cause unexpected prolongation of vecuronium-induced neuromuscular blockade.

Aminoglycoside eliminated by active tubular secretion; coadministration may increase tenofovir and gentamicin concentrations, increasing adverse reaction risk.

Coadministration may increase concentrations of gentamicin and renally eliminated drugs, increasing risk of adverse reactions.

May potentiate renal dysfunction when used concomitantly with cyclosporine. Close monitoring of renal function required.

In vitro study showed cytarabine-related antagonism of gentamicin susceptibility against K. pneumoniae. Lack of prompt therapeutic response may indicate need for re-evaluation of antibacterial therapy.

Aminoglycoside eliminated by active tubular secretion; may increase concentrations of gentamicin and/or emtricitabine/tenofovir.

Coadministration may increase concentrations of tenofovir and/or gentamicin due to competition for active tubular secretion in the kidneys.

Gentamicin (aminoglycoside) is eliminated by active tubular secretion; coadministration may increase concentrations of gentamicin and emtricitabine/tenofovir, increasing risk of adverse reactions.

Aminoglycoside coadministration may increase concentrations of FTC, tenofovir, and gentamicin due to competition for active tubular secretion.

Coadministration may increase concentrations of aminoglycosides and/or tenofovir due to competition for renal tubular secretion. Monitor for tenofovir toxicity.

Coadministration may increase serum concentrations of emtricitabine, tenofovir, and/or gentamicin due to competition for renal tubular secretion.

Coadministration may increase serum concentrations of FTC, tenofovir, and/or gentamicin due to competition for active tubular secretion.

Coadministration may increase concentrations of FTC, tenofovir, and/or gentamicin due to competition for active tubular secretion in kidneys.

Aminoglycoside that may increase serum tenofovir concentrations and/or increase concentrations of other renally eliminated drugs.

Piperacillin and tazobactam may inactivate gentamicin in vitro. Separate administration is recommended, though compatibility exists for simultaneous Y-site infusion in certain diluents and concentrations.

Coadministration may increase tenofovir concentrations due to active tubular secretion competition. Monitor for evidence of tenofovir toxicity.

Animal data suggested possible interaction between perindopril and gentamicin, but not investigated in human studies.